...
首页> 外文期刊>Journal of Pharmacy and Pharmacology >The influence of improved glycaemic control with chlorpropamide on microvascular reactivity and nitric oxide synthase activity in diabetic rats.
【24h】

The influence of improved glycaemic control with chlorpropamide on microvascular reactivity and nitric oxide synthase activity in diabetic rats.

机译:氯丙酰胺改善血糖控制对糖尿病大鼠微血管反应性和一氧化氮合酶活性的影响。

获取原文
获取原文并翻译 | 示例
           

摘要

Hyperglycaemia is a primary cause of vascular complications in diabetes. A hallmark of these vascular complications is endothelial cell dysfunction, which is partly due to reduced production of nitric oxide. The aim of this study was to verify the influence of improved glycaemic control with chlorpropamide on microvascular reactivity, endothelial nitric oxide synthase (e-NOS) expression, and NOS activity in neonatal streptozotocin-induced diabetic rats (n-STZ). Diabetes was induced by STZ injection into neonates Wistar rats. n-STZ diabetic rats were treated with chlorpropamide (200 mg kg(-1), 15 days, by gavage). The changes in mesenteric arteriolar and venular diameters were determined in anaesthetized control and n-STZ diabetic rats, before and after topical application of acetylcholine, bradykinin and sodium nitroprusside (SNP). We also assessed e-NOS expression (using polymerase chain reaction after reverse transcription of mRNAs into cDNAs) and NOS activity (conversion of L-arginine to citrulline)in the mesenteric vascular bed of chlorpropamide-treated n-STZ, vehicle-treated n-STZ, and control rats. In n-STZ, chlorpropamide treatment reduced high glycaemic levels, improved glucose tolerance and homoeostatic model assessment (HOMA-beta), and restored NOS activity. Impaired vasodilator responses of arterioles and venules to acetylcholine, bradykinin and SNP were partially corrected by chlorpropamide treatment in n-STZ. We concluded that improved metabolic control and restored NOS activity might be collaborating with improved microvascular reactivity found in chlorpropamide-treated n-STZ.
机译:高血糖是糖尿病血管并发症的主要原因。这些血管并发症的标志是内皮细胞功能障碍,部分原因是一氧化氮的产生减少。这项研究的目的是验证氯丙酰胺改善血糖控制对新生的链脲佐菌素诱导的糖尿病大鼠(n-STZ)的微血管反应性,内皮一氧化氮合酶(e-NOS)表达和NOS活性的影响。通过将STZ注射到新生Wistar大鼠中来诱发糖尿病。 n-STZ糖尿病大鼠用氯丙酰胺(200 mg kg(-1),经管饲15天)治疗。在局部应用乙酰胆碱,缓激肽和硝普钠(SNP)之前和之后,在麻醉对照组和n-STZ糖尿病大鼠中确定肠系膜小动脉和静脉直径的变化。我们还评估了氯丙酰胺处理过的n-STZ,媒介物处理过的n-STZ肠系膜血管床中e-NOS的表达(使用mRNA逆转录成cDNA后的聚合酶链反应)和NOS活性(L-精氨酸转化为瓜氨酸)。 STZ和对照组。在n-STZ中,氯丙酰胺治疗可降低高血糖水平,改善葡萄糖耐量和稳态模型评估(HOMA-beta),并恢复NOS活性。在n-STZ中,通过氯丙酰胺治疗可部分纠正小动脉和小静脉对乙酰胆碱,缓激肽和SNP的血管舒张反应受损。我们得出的结论是,改善的代谢控制和恢复的NOS活性可能与氯丙酰胺处理过的n-STZ中改善的微血管反应性有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号